FEV1 (% predicted): mean change from baseline · children (12 or over) and young adults with cystic fibrosis
Summary of findings: nitric oxide showed no clear difference in respiratory function mean change in FEV1 % predicted from baseline compared with placebo (low certainty).
1 finding from 1 review
Adverse events · children (12 or over) and young adults with cystic fibrosis
It is very uncertain whether summary of findings: nitric oxide changes adverse events compared with placebo (very low certainty).
1 finding from 1 review
QoL · children (12 or over) and young adults with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Sputum microbiology · children (12 or over) and young adults with cystic fibrosis
1 finding from 1 review
Inflammatory markers · children (12 or over) and young adults with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adults and children with cystic fibrosis
1 finding from 1 review
FEV1 % predicted · children with cystic fibrosis
It is very uncertain whether summary of findings: Zinc supplementation changes respiratory function mean FEV1 % predicted compared with placebo (very low certainty).
1 finding from 1 review
Adverse events number of participants hospitalised during the trial · children with cystic fibrosis
Summary of findings: Zinc supplementation showed no clear difference in adverse events number of participants hospitalised during the trial compared with placebo (moderate certainty).
1 finding from 1 review
QoL · children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Sputum microbiology · children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Inflammatory markers · children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
QoL · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Sputum microbiology · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Inflammatory markers · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pulmonary exacerbations · children aged over eight and adults with cystic fibrosis and chronic pulmonary infection with P aeruginosa
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
FEV1 (% predicted): mean change from baseline · children aged over eight and adults with cystic fibrosis and chronic pulmonary infection with P aeruginosa
Summary of findings: garlic supplementation showed no clear difference in respiratory function change from baseline in % predicted FEV1 compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
FEV1 change from start of treatment (L) · adults and children with cystic fibrosis and P aeruginosa
1 finding from 1 review
Intervention not reported
FEV1 change from start of treatment (% predicted) · adults and children with cystic fibrosis and P aeruginosa
1 finding from 1 review
Intervention not reported
Time to next exacerbation · adults and children with cystic fibrosis and P aeruginosa
1 finding from 1 review
Intervention not reported
Adverse events: number of moderate adverse events · adults and children with cystic fibrosis and P aeruginosa
The intervention showed no clear difference in adverse events: number of moderate adverse events (moderate certainty).
1 finding from 1 review